home > ict > summer 2018 > protecting privacy
International Clinical Trials

Protecting Privacy

ICT: Would you say that attitudes towards data protection are hardening? If so, why?

Dr Andrew Rut: Data privacy is one of the most contentious issues of our time. Global attitudes towards the protection and ownership of personal data are toughening, and this is reflected in increased regulation. For example, the EU’s General Data Protection Regulation (GDPR), which was introduced in May 2018, expands existing rules in areas such as patient consent and imposes tough penalties for noncompliance.

The shift is happening because, while new technologies have enabled the capture of data at an unprecedented volume and rate, adequate systems to protect individuals’ personal information have not always developed in step. High-profile data breaches − such as SingHealth, where 1.5 million healthcare patients, including the Singaporean prime minister, had their personal data leaked − have raised awareness of the huge value of data and the need for increasingly robust security measures to protect it (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Dr Andrew Rut is CEO and Co-Founder of MyMeds&Me: a provider of Reportum. Andrew has deep expertise in pharmacovigilance, as well as the emerging challenges of data privacy, participating in numerous conferences and benchmarking initiatives. He is a trained physician who has held leadership roles spanning drug discovery and development within GSK, working across three continents: the US, Europe, and Asia-Pacific. He was previously Head of Safety at GSK and the EU Qualified Person Responsible for Pharmacovigilance, where he drove significant innovation and streamlining into the organisation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement